Loading data for PRTA — first visit, this takes a few seconds.
Prothena Corporation plc (PRTA)
NasdaqGS: PRTA
· 即時價格 · USD
9.69
+0.08 (0.83%)
收盤價： Sep 04, 2026, 8:00 PM
9.75
-0.71%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Prothena Corporation plc（PRTA）股價、分析與資料
無可用資料
| 買價 | 6.97 |
| 市值 | 504M |
| 營收 (ttm) | 54.5M |
| 淨利（ttm） | -44M |
| -0.33 | |
| -0.82 | |
| n/a | |
| -6.46 | |
| P/B (ttm) | 1.77 |
| P/S (ttm) | 9.24 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 12.08 |
| 成交量 | 341,054 |
| 20 日平均成交量 | 521,895 |
| 開盤價 | 9.64 |
| 前收盤價 | 9.61 |
| 當日區間 | 9.37 - 9.75 |
| 52 週範圍 | 7.73 - 11.80 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PRTA
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is...
完整的公司簡介財報驚奇
Prothena plc 已於 Aug 6, 2026 公布季度財報：
- 營收為 $1.01M 低於預期 $0, 年增 -77.15% 下滑.
- 每股盈餘為 -0.31 超出預期 0.07, 年增 82.08% 成長.
第 1 頁，共 2 頁